Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Cresco Labs ( (TSE:CL) ).
Cresco Labs has welcomed the U.S. federal government’s decision to move cannabis from Schedule I to Schedule III, calling it the most consequential milestone in the history of the American cannabis sector. CEO Charlie Bachtell said rescheduling recognizes cannabis as medicine, narrows the gap between federal law and widespread state-level legalization, and is expected to ease punitive tax treatment, enable more robust medical research, and lay the foundation for future reforms in banking access and capital markets. The company argues the policy shift will validate state regulatory frameworks, support the roughly 450,000 workers in the regulated cannabis industry and help normalize cannabis as a mainstream U.S. industry, reinforcing Cresco’s strategy of building respected national brands and expanding its operational footprint in a more accommodating federal environment.
The most recent analyst rating on (TSE:CL) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Cresco Labs stock, see the TSE:CL Stock Forecast page.
Spark’s Take on TSE:CL Stock
According to Spark, TipRanks’ AI Analyst, TSE:CL is a Neutral.
Cresco Labs’ overall stock score is primarily impacted by its financial performance, which is challenged by declining revenues, high leverage, and persistent net losses. Technical analysis provides mixed signals, with an overbought RSI and positive moving average trends. Valuation concerns are significant due to a negative P/E ratio and lack of dividend yield. The earnings call, while excluded from the weighted calculation, indicates strategic initiatives that could improve future performance.
To see Spark’s full report on TSE:CL stock, click here.
More about Cresco Labs
Cresco Labs is a U.S.-based, vertically integrated cannabis company focused on normalizing and professionalizing the medical marijuana industry through a consumer packaged goods approach to national brands and patient-focused retail. It operates cultivation, production and branded product distribution businesses, marketing labels such as Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy’s and Remedi, and runs Sunnyside-branded dispensaries across the country, while actively engaging in policy, community outreach and workforce development initiatives to shape a highly regulated cannabis market.
Average Trading Volume: 327,549
Technical Sentiment Signal: Buy
Current Market Cap: C$1.08B
For a thorough assessment of CL stock, go to TipRanks’ Stock Analysis page.